Arizona · 81329

Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion in Arizona

Arizona Medicare Avg
$134.26
0% above national avg
National Medicare Avg
$134.14
All states combined
Billed Charge (AZ)
$175.00
What providers submit
Est. Commercial (AZ)
$306.11
National avg: $300.48
Est. Cash / Self-Pay (AZ)
$148.82
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

60
Services in AZ
1
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Arizona

Provider Medicare Services
Genetic Technological Innovations,... $134.26 60

Arizona Pricing in Context

In Arizona, CPT code 81329 (Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion) carries an average Medicare payment of $134.26 — 0% above the national benchmark of $134.14. 1 providers across the state submitted claims for this procedure in 2023, performing 60 total services. Individual payments in AZ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Arizona is $175.00, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Arizona sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Arizona lands near $306.11, with self-pay cash prices typically around $148.82. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion cost in Arizona?

The average Medicare payment for Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion in Arizona is $134.26, which is 0% above the national average of $134.14. Providers in AZ typically bill $175.00 for this procedure.

What does Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion cost with insurance in Arizona?

With commercial insurance in Arizona, Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion costs an estimated $306.11. Without insurance, the estimated cash price is $148.82. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion in Arizona?

1 providers in Arizona billed Medicare for Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion in 2023, performing 60 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion cheaper in Arizona than the national average?

No — Gene Analysis (survival Of Motor Neuron 1, Telomeric) For Dosage/deletion costs 0% above the national average in Arizona. The state average Medicare payment is $134.26 compared to $134.14 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial